HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons

The review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin (Epo) and activate erythropoiesis by stabilizing and activating the hypoxia in...

Full description

Bibliographic Details
Main Authors: Andrey A. Poloznikov, Stepan A. Nersisyan, Dmitry M. Hushpulian, Eliot H. Kazakov, Alexander G. Tonevitsky, Sergey V. Kazakov, Valery I. Vechorko, Sergey V. Nikulin, Julia A. Makarova, Irina G. Gazaryan
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.621054/full
id doaj-861906911e074ab98b8dd5ba057316b3
record_format Article
spelling doaj-861906911e074ab98b8dd5ba057316b32021-01-29T04:34:15ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-01-011110.3389/fphar.2020.621054621054HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and ConsAndrey A. Poloznikov0Stepan A. Nersisyan1Dmitry M. Hushpulian2Dmitry M. Hushpulian3Eliot H. Kazakov4Alexander G. Tonevitsky5Sergey V. Kazakov6Valery I. Vechorko7Sergey V. Nikulin8Julia A. Makarova9Irina G. Gazaryan10Irina G. Gazaryan11Irina G. Gazaryan12Irina G. Gazaryan13Faculty of Biology and Biotechnology, HSE University, Moscow, RussiaFaculty of Biology and Biotechnology, HSE University, Moscow, RussiaP. A. Hertsen Moscow Oncology Research Center, Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow, RussiaSchool of Biomedicine, Far Eastern Federal University, Vladivostok, RussiaDepartment of Anatomy and Cell Biology, New York Medical College, Valhalla, NY, United StatesFaculty of Biology and Biotechnology, HSE University, Moscow, RussiaDepartment of Chemistry and Physical Sciences, Dyson College of Arts and Sciences, Pace University, Pleasantville, NY, United StatesCity Clinical Hospital No 15 Named After O. M. Filatov, Moscow, RussiaFaculty of Biology and Biotechnology, HSE University, Moscow, RussiaFaculty of Biology and Biotechnology, HSE University, Moscow, RussiaP. A. Hertsen Moscow Oncology Research Center, Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow, RussiaDepartment of Anatomy and Cell Biology, New York Medical College, Valhalla, NY, United StatesDepartment of Chemistry and Physical Sciences, Dyson College of Arts and Sciences, Pace University, Pleasantville, NY, United StatesChemical Enzymology Department, M. V. Lomonosov Moscow State University, Moscow, RussiaThe review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin (Epo) and activate erythropoiesis by stabilizing and activating the hypoxia inducible factor (HIF). Recombinant Epo treatment has anti-inflammatory and healing properties, and thus, very likely, will be beneficial for moderate to severe cases of COVID-19. However, HIF PHD inhibition may have a significantly broader effect, in addition to stimulating the endogenous Epo production. The analysis of HIF target genes reveals that some HIF-targets, such as furin, could play a negative role with respect to viral entry. On the other hand, HIF prolyl hydroxylase inhibitors counteract ferroptosis, the process recently implicated in vessel damage during the later stages of COVID-19. Therefore, HIF prolyl hydroxylase inhibitors may serve as a promising treatment of COVID-19 complications, but they are unlikely to aid in the prevention of the initial stages of infection.https://www.frontiersin.org/articles/10.3389/fphar.2020.621054/fullSARS-CoVhypoxia inducible factorroxadustatvadadustatadaptaquinneuradapt
collection DOAJ
language English
format Article
sources DOAJ
author Andrey A. Poloznikov
Stepan A. Nersisyan
Dmitry M. Hushpulian
Dmitry M. Hushpulian
Eliot H. Kazakov
Alexander G. Tonevitsky
Sergey V. Kazakov
Valery I. Vechorko
Sergey V. Nikulin
Julia A. Makarova
Irina G. Gazaryan
Irina G. Gazaryan
Irina G. Gazaryan
Irina G. Gazaryan
spellingShingle Andrey A. Poloznikov
Stepan A. Nersisyan
Dmitry M. Hushpulian
Dmitry M. Hushpulian
Eliot H. Kazakov
Alexander G. Tonevitsky
Sergey V. Kazakov
Valery I. Vechorko
Sergey V. Nikulin
Julia A. Makarova
Irina G. Gazaryan
Irina G. Gazaryan
Irina G. Gazaryan
Irina G. Gazaryan
HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
Frontiers in Pharmacology
SARS-CoV
hypoxia inducible factor
roxadustat
vadadustat
adaptaquin
neuradapt
author_facet Andrey A. Poloznikov
Stepan A. Nersisyan
Dmitry M. Hushpulian
Dmitry M. Hushpulian
Eliot H. Kazakov
Alexander G. Tonevitsky
Sergey V. Kazakov
Valery I. Vechorko
Sergey V. Nikulin
Julia A. Makarova
Irina G. Gazaryan
Irina G. Gazaryan
Irina G. Gazaryan
Irina G. Gazaryan
author_sort Andrey A. Poloznikov
title HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
title_short HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
title_full HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
title_fullStr HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
title_full_unstemmed HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
title_sort hif prolyl hydroxylase inhibitors for covid-19 treatment: pros and cons
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2021-01-01
description The review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin (Epo) and activate erythropoiesis by stabilizing and activating the hypoxia inducible factor (HIF). Recombinant Epo treatment has anti-inflammatory and healing properties, and thus, very likely, will be beneficial for moderate to severe cases of COVID-19. However, HIF PHD inhibition may have a significantly broader effect, in addition to stimulating the endogenous Epo production. The analysis of HIF target genes reveals that some HIF-targets, such as furin, could play a negative role with respect to viral entry. On the other hand, HIF prolyl hydroxylase inhibitors counteract ferroptosis, the process recently implicated in vessel damage during the later stages of COVID-19. Therefore, HIF prolyl hydroxylase inhibitors may serve as a promising treatment of COVID-19 complications, but they are unlikely to aid in the prevention of the initial stages of infection.
topic SARS-CoV
hypoxia inducible factor
roxadustat
vadadustat
adaptaquin
neuradapt
url https://www.frontiersin.org/articles/10.3389/fphar.2020.621054/full
work_keys_str_mv AT andreyapoloznikov hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons
AT stepananersisyan hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons
AT dmitrymhushpulian hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons
AT dmitrymhushpulian hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons
AT eliothkazakov hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons
AT alexandergtonevitsky hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons
AT sergeyvkazakov hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons
AT valeryivechorko hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons
AT sergeyvnikulin hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons
AT juliaamakarova hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons
AT irinaggazaryan hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons
AT irinaggazaryan hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons
AT irinaggazaryan hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons
AT irinaggazaryan hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons
_version_ 1724318953359015936